amphetamine · Neos Theraps Inc · NDA 204325
Adzenys Er
Earliest generic entry, as listed
28 Jun 2032
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 8709491, US 9017731, US 9265737.
Listed patents · 3 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 8709491 | drug product · sets the listed date | 28 Jun 2032 |
| US 9017731 | drug product · sets the listed date | 28 Jun 2032 |
| US 9265737 | drug product · sets the listed date | 28 Jun 2032 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 204325 · 001 · RLD · discontinued | suspension, extended release, oral | EQ 1.25MG BASE/ML | 28 Jun 2032 |